Cargando…
Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
BACKGROUND: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. METHODS: We performed a multicenter prospective trial in patients with type 2 diabetes...
Autores principales: | Chiba, Yukari, Yamakawa, Tadashi, Tsuchiya, Hirohisa, Oba, Mari, Suzuki, Daisuke, Danno, Hirosuke, Takatsuka, Yoji, Shigematsu, Hiroshi, Kaneshiro, Mizuki, Terauchi, Yasuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031245/ https://www.ncbi.nlm.nih.gov/pubmed/29977423 http://dx.doi.org/10.14740/jocmr3464w |
Ejemplares similares
-
Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome
por: Amagai, Mari, et al.
Publicado: (2017) -
Association of usual sleep quality and glycemic control in type 2 diabetes in Japanese: A cross sectional study. Sleep and Food Registry in Kanagawa (SOREKA)
por: Sakamoto, Rika, et al.
Publicado: (2018) -
A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes
por: Shigematsu, Erina, et al.
Publicado: (2017) -
Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014) -
Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial
por: Iijima, Takahiro, et al.
Publicado: (2020)